Skip to main content
SpringerLink
Log in
Book cover

Adjuvant Therapy of Primary Breast Cancer VI pp 314–322Cite as

Putting Taxanes to Work in Operable Breast Cancer: A Search for Selective Indications from Empirical Studies

  • Conference paper

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 152))

Abstract

Based on their unique and novel mechanism of action, the taxanes paclitaxel (PCT) and docetaxel (DCT) have been extensively studied in solid tumors. The two drugs found in the field of breast cancer an arena of most intensive investigation (Gianni and Capri 1997). The huge body of studies and reports in the literature has prompted enthusiasm, some concern and occasionally confusion on the actual role of the two drugs in breast cancer. The risk of the unprecedented investigational effort on taxanes in breast cancer is one of generating confusion, due to their already widespread use when key aspects of their pharmacology and their optimal application are still undefined. This risk is very much present in the case of adjuvant or neo-adjuvant use of PCT and DCT. Some remarks may help in putting the problems into perspective.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Baselga J, Seidman AD, Rosen PP et al (1997) HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt) 11:43–48

    CAS  Google Scholar 

  • Belotti D, Vergani V, Drudis T et al (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843–1849

    PubMed  CAS  Google Scholar 

  • Bishop JF, Dewar J, Tattersall MH et al (1997) Taxol alone is equivalent to CMFP combination chemotherapy as frontline treatment in metastatic breast cancer. Proc Am Soc Clin Oncol 16:153a (abstract 538)

    Google Scholar 

  • Bonadonna G, Zambetti M, Valagussa P (1995) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273:542–547

    Article  PubMed  CAS  Google Scholar 

  • Bonadonna G, Valagussa P, Brambilla C et al (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93–100

    PubMed  CAS  Google Scholar 

  • Bourgeois H, Gruia G, Dieras V et al (1996) Docetaxel in combination with doxorubicin as first line CT of metastatic breast cancer. Proc Am Soc Clin Oncol 15:148 (abstract 259)

    Google Scholar 

  • Conte PF, Baldini E, Gennari A et al (1997) Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 15:2510–2517

    PubMed  CAS  Google Scholar 

  • Dombernowsky P, Gehl J, Boesgaard M et al (1996) Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 23(Suppl 1):13–18

    PubMed  CAS  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339 (i):71–85

    Google Scholar 

  • Fisher B, Brown A, Mamoimas E et al (1997a) Effect of preoperative therapy for primary breast cancer on local-regional disease, disease-free survival and survival: results from NSABP B-18. Proc Am Soc Clin Oncol 16:127a (abstract 449)

    Google Scholar 

  • Fisher B, Dignam J, Wolmark N et al (1997b) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673–1682

    Article  PubMed  CAS  Google Scholar 

  • Frassinetti GL, Zoli W, Tienghi A et al (1996) Phase I/II study of sequential combination of paclitaxel and doxorubicin in the treatment of advanced breast cancer. Proc Am Soc Clin Oncol 15:109

    Google Scholar 

  • Gasparini G, Toi M, Gion M et al (1997) Prognostic significance of vascular endothelial growht factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89:139–147

    Article  PubMed  CAS  Google Scholar 

  • Gianni L (1995) Theoretical and practical aspects of paclitaxel scheduling. Ann Oncol 6:861–863

    PubMed  CAS  Google Scholar 

  • Gianni L (1997) Future directions of paclitaxel-based therapy of breast cancer. Semin Oncol 24 Suppl 17:91–96

    CAS  Google Scholar 

  • Gianni L, Capri G (1997a) Experience at the Istituto Nationale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer. Semin Oncol 24 Suppl 3:1–3

    Google Scholar 

  • Gianni L, Capri G (1997b) In: Bonadonna G, Hortobagyi GN, Gianni AM (eds) Textbook of breast cancer: a clinical guide to therapy. Martin Dunitz, London, pp 253–280

    Google Scholar 

  • Gianni L, Munzone E, Capri G et al (1995a) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688–2699

    PubMed  CAS  Google Scholar 

  • Gianni L, Munzone E, Capri G et al (1995b) Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87:1169–1175

    Article  PubMed  CAS  Google Scholar 

  • Henderson IC, Berry D, Demetri G et al (1998) Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose-level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am Soc Clin Oncol 17:101a

    Google Scholar 

  • Hudis CA, Seidman A, Raptis G et al (1996) Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 23 (Suppl 1):58–64

    PubMed  CAS  Google Scholar 

  • Klauber N, Parangi S, Flynn E et al (1997) Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57:81–86

    PubMed  CAS  Google Scholar 

  • Moliterni A, Tarenzi E, Capri G et al (1997) Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Semin Oncol 24 (Suppl 17):10–14

    CAS  Google Scholar 

  • Muss HB, Thor AD, Berry DA et al (1994) c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. (Published erratum appears in N Engl J Med 1994::331:211). N Engl J med 330:1260–1266

    Article  PubMed  CAS  Google Scholar 

  • Nabholtz JM, Gelmon K, Spielmann M et al (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858–1867

    PubMed  CAS  Google Scholar 

  • Ravdin PM (1995) Taxoids: effective agents in anthracycline-resistant breast cancer. Semin Oncol 22 (Suppl 13):29–34

    PubMed  CAS  Google Scholar 

  • Ravdin PM, Burris HA, Cook G et al (1995) Phase II tirai of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879–2885

    PubMed  CAS  Google Scholar 

  • Schwartsmann G, Menke CH, Caleffi M et al (1996) Phase II trial of taxol (T), doxorubicin (D) plus G-CSF in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 15:126

    Google Scholar 

  • Seidman AD (1995) The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 1:247–256

    PubMed  CAS  Google Scholar 

  • Seidman AD, Reichman BS, Crown JPA et al (1995) Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13:1152–1159

    PubMed  CAS  Google Scholar 

  • Seidman AD, Baselga J, Yao T-Y et al (1996) HER2-/neu over expression and clinical taxane sensitivity: a multivariate analysis in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 15:104 (abstract 80)

    Google Scholar 

  • Slamon D, Leyland-Jones B, Shak S et al (1998) Addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized international controlled Phase III trial. Proc Am Soc Clin Oncol 17:98a

    Google Scholar 

  • Sledge GW, Neuberg D, Ingle J et al (1997) Phase III trial of doxorubicin vs paclitaxel vs doxorubicin plus paclitaxel as first-line therapy for metastatic breast cancer: an intergroup trial. Proc Am Soc Clin Oncol 16:1a (abstract 2)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisione di Oncologia Medica, Istituto Nazionale Tumori, 20133, Milan, Italy

    L. Gianni, G. Capri, P. Valagussa & G. Bonadonna

Authors
  1. L. Gianni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Capri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Valagussa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Bonadonna
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Zentrum für Tumordiagnostik und Prävention, Rorschacherstrasse 150, CH-9006, St. Gallen, Switzerland

    Hans-Jörg Senn

  2. Dana Farber Cancer Institute Biostatistics, 44 Binney Street, Boston, 02115, USA

    Richard D. Gelber Ph.D

  3. Ospedale Civico, CH-6900, Lugano, Switzerland

    Aron Goldhirsch

  4. Klinik C für Innere Medizin Abteilung für Onkologie und Hämatologie, Kantonsspital St. Gallen, CH-9007, St. Gallen, Switzerland

    Beat Thürlimann

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin · Heidelberg

About this paper

Cite this paper

Gianni, L., Capri, G., Valagussa, P., Bonadonna, G. (1998). Putting Taxanes to Work in Operable Breast Cancer: A Search for Selective Indications from Empirical Studies. In: Senn, HJ., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Primary Breast Cancer VI. Recent Results in Cancer Research, vol 152. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45769-2_30

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-45769-2_30

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-45771-5

  • Online ISBN: 978-3-642-45769-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation